Caribou Biosciences Stock Total Debt
| CRBU Stock | USD 1.20 0.04 3.23% |
Caribou Biosciences fundamentals help investors to digest information that contributes to Caribou Biosciences' financial success or failures. It also enables traders to predict the movement of Caribou Stock. The fundamental analysis module provides a way to measure Caribou Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Caribou Biosciences stock.
Total Debt To Capitalization is likely to gain to 0.06 in 2025. Caribou | Total Debt |
Caribou Biosciences Company Total Debt Analysis
Caribou Biosciences' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Caribou Biosciences Total Debt | 27.11 M |
Most of Caribou Biosciences' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Caribou Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Caribou Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Caribou Biosciences is extremely important. It helps to project a fair market value of Caribou Stock properly, considering its historical fundamentals such as Total Debt. Since Caribou Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Caribou Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Caribou Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Caribou Total Debt Historical Pattern
Today, most investors in Caribou Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Caribou Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Caribou Biosciences total debt as a starting point in their analysis.
Caribou Biosciences Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Caribou Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Caribou Biosciences has a Total Debt of 27.11 M. This is 99.01% lower than that of the Biotechnology sector and 91.65% lower than that of the Health Care industry. The total debt for all United States stocks is 99.49% higher than that of the company.
Caribou Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Caribou Biosciences' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics of similar companies.Caribou Biosciences is currently under evaluation in total debt category among its peers.
Caribou Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Caribou Biosciences from analyzing Caribou Biosciences' financial statements. These drivers represent accounts that assess Caribou Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Caribou Biosciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 964.3M | 669.2M | 351.2M | 398.9M | 458.7M | 730.8M |
Caribou Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Caribou Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Caribou Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Caribou Biosciences' value.| Shares | Fmr Inc | 2024-12-31 | 1.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.5 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.2 M | Two Sigma Investments Llc | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 1.1 M | Point72 Asset Management, L.p. | 2024-12-31 | 1 M | Jpmorgan Chase & Co | 2024-09-30 | 866.7 K | Fidelity International Ltd | 2024-09-30 | 860.7 K | Millennium Management Llc | 2024-12-31 | 859.8 K | Blackrock Inc | 2024-12-31 | 6.6 M | Vanguard Group Inc | 2024-12-31 | 4.6 M |
Caribou Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (16.67) % | ||||
| Current Valuation | (88.8 M) | ||||
| Shares Outstanding | 90.55 M | ||||
| Shares Owned By Insiders | 10.14 % | ||||
| Shares Owned By Institutions | 63.28 % | ||||
| Number Of Shares Shorted | 8.86 M | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 9.79 X | ||||
| Revenue | 34.48 M | ||||
| Gross Profit | (119.49 M) | ||||
| EBITDA | (112.53 M) | ||||
| Net Income | (102.07 M) | ||||
| Cash And Equivalents | 339.92 M | ||||
| Cash Per Share | 5.59 X | ||||
| Total Debt | 27.11 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.23 X | ||||
| Book Value Per Share | 3.10 X | ||||
| Cash Flow From Operations | (93.29 M) | ||||
| Short Ratio | 5.35 X | ||||
| Earnings Per Share | (1.66) X | ||||
| Price To Earnings To Growth | 0.50 X | ||||
| Target Price | 13.25 | ||||
| Number Of Employees | 158 | ||||
| Beta | 2.31 | ||||
| Market Capitalization | 112.29 M | ||||
| Total Asset | 432.21 M | ||||
| Retained Earnings | (299.29 M) | ||||
| Working Capital | 310.54 M | ||||
| Net Asset | 432.21 M |
About Caribou Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Caribou Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.